Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)

Main Article Content

Eric L Simpson
Hiroyuki Fujita
Kazuhiko Arima
Jennifer Hamilton
Yufang Lu
Ana B Rossi
Ashish Bansal

Keywords

Atopic Dermatitis, Biologics, Dupilumab, Biomarker

Abstract

Abstract not available.

References

1. Eichenfield LF, et al. J Am Acad Dermatol. 2014;70:338-51.

2. Kakinuma T, et al. J Allergy Clin Immunol. 2001; 107:535-41.

3. Jahnz-Rozyk K, et al. Allergy. 2005; 60:685-8.

4. Thijs JL, et al. Immunol Allergy Clin North Am. 2017; 37:51-61.

5. Macdonald LE, et al. Proc Natl Acad Sci U S A. 2014;111:5147-52.

6. Murphy AJ, et al. Proc Natl Acad Sci U S A. 2014;111:5153-8.

7. Gandhi NA, et al. Expert Rev Clin Immunol. 2017;13:425-37.

8. Simpson EL, et al. JAMA Dermatol. In press 2019.

9. Yosipovitch G, et al. Br J Dermatol. 2019;181:761-9.

10. Yosipovitch G, et al. Exp Dermatol. 2018;27 Suppl 2:S98.